The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech ...

Life science leaders with rounded corners lead to more enduring progress than razor-sharp perfection ever could, writes Tara ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...

On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and ...

Delivering reliable, high-quality software at speed requires more than fast coding—it demands a smarter approach to testing. That’s where the Shift-Left methodology comes in. By moving testing ...

France's Early Access Program (EAP) is a critical pathway for patients with severe or rare conditions to swiftly access innovative therapies, having granted over 120,000 patients early access since ...

The patient perspective is now a critical component in assessing the value of new therapies, moving beyond traditional reliance on strictly clinical endpoints like mortality and tumor shrinkage.